Sep 21, 2026 5 0
Uploaded by Noah
Favorite
Share
More Options
19
Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer - a phase I/Ib study_Page 1

Open in WPS to view all 19 pages